WO2009156182A3 - Uracilderivate und deren verwendung - Google Patents

Uracilderivate und deren verwendung Download PDF

Info

Publication number
WO2009156182A3
WO2009156182A3 PCT/EP2009/004698 EP2009004698W WO2009156182A3 WO 2009156182 A3 WO2009156182 A3 WO 2009156182A3 EP 2009004698 W EP2009004698 W EP 2009004698W WO 2009156182 A3 WO2009156182 A3 WO 2009156182A3
Authority
WO
WIPO (PCT)
Prior art keywords
uracil derivatives
uracil
derivatives
cytostatic
suppressing
Prior art date
Application number
PCT/EP2009/004698
Other languages
English (en)
French (fr)
Other versions
WO2009156182A2 (de
Inventor
Rudolf Fahrig
Kurt Eger
Martin FÜHRER
Nicole Heinze
Matthias Klemm
Jörg-Christian HEINRICH
Original Assignee
Resprotect Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resprotect Gmbh filed Critical Resprotect Gmbh
Priority to EP09769031A priority Critical patent/EP2303848A2/de
Priority to US13/000,900 priority patent/US9181199B2/en
Publication of WO2009156182A2 publication Critical patent/WO2009156182A2/de
Publication of WO2009156182A3 publication Critical patent/WO2009156182A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Die Erfindung betrifft Uracilderivate sowie deren Anwendung als therapeutischer Wirkstoff. Die Uracilderivate werden dabei insbesondere zusammen mit einem Zytostatikum zur Unterdrückung oder Reduzierung der Resistenzenbildung bei der Zytostatikabehandlung eingesetzt.
PCT/EP2009/004698 2008-06-25 2009-06-25 Uracilderivate und deren verwendung WO2009156182A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09769031A EP2303848A2 (de) 2008-06-25 2009-06-25 Uracilderivate und deren verwendung
US13/000,900 US9181199B2 (en) 2008-06-25 2009-06-25 Uracil derivatives and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008030091A DE102008030091B4 (de) 2008-06-25 2008-06-25 Uracilderivate und deren Verwendung
DE102008030091.8 2008-06-25

Publications (2)

Publication Number Publication Date
WO2009156182A2 WO2009156182A2 (de) 2009-12-30
WO2009156182A3 true WO2009156182A3 (de) 2010-03-11

Family

ID=41351434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/004698 WO2009156182A2 (de) 2008-06-25 2009-06-25 Uracilderivate und deren verwendung

Country Status (4)

Country Link
US (1) US9181199B2 (de)
EP (1) EP2303848A2 (de)
DE (1) DE102008030091B4 (de)
WO (1) WO2009156182A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103242242A (zh) * 2012-02-08 2013-08-14 河南师范大学 5-位缺电子烯基取代嘧啶碳环核苷及制备方法
CN103242400B (zh) * 2012-02-08 2016-06-08 河南师范大学 具有抗hiv活性的5-取代嘧啶核苷-噻唑啉酮杂化体及其制备方法
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
EP3066098A1 (de) 2013-11-08 2016-09-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
US9695131B2 (en) 2013-11-08 2017-07-04 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
US20170216297A1 (en) 2014-07-28 2017-08-03 Technische Universitaet Dresden Efficient inhibition of hsp27
EP3133065A1 (de) 2015-08-21 2017-02-22 Merck Patent GmbH Verbindungen für optisch aktive vorrichtungen
EP3363793A1 (de) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobe verbindungen zur herstellung von optisch aktiven vorrichtungen
EP3819006A1 (de) 2019-11-05 2021-05-12 Technische Universität Dresden Verbindungen mit thymin-gerüst zur verwendung in der medizin
US20230273455A1 (en) 2020-07-15 2023-08-31 Johnson & Johnson Surgical Vision, Inc. Optically active devices

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023506A1 (de) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2006070292A2 (en) * 2004-10-12 2006-07-06 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2008145562A1 (en) * 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD202873A1 (de) * 1981-08-25 1983-10-05 Akad Wissenschaften Ddr Verfahren zur herstellung von 5-(2,2-disubstituierten) uracilderivaten
DE3912100A1 (de) * 1989-04-13 1990-10-25 Bayer Ag Substituierte uracile, verfahren zu ihrer herstellung und verwendung gegen parasitaere protozoen
DK0748800T3 (da) 1995-06-09 2001-08-27 Hoffmann La Roche Pyrimidindion-, pyrimidintrion- og triazindionderivater som alfa-1-adrenergiske receptorantagonister
MXPA02000763A (es) * 1999-07-22 2002-08-12 Newbiotics Inc Activacion terapeutica catalizada por enzima.
JP4931314B2 (ja) * 2000-01-25 2012-05-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法
CA2570968A1 (en) * 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023506A1 (de) * 1995-02-01 1996-08-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verwendung von 5' substituierten nukleosiden zur hemmung von resistenzbildung bei der zytostatikabehandlung und arzneimittel, enthaltend diese nukleoside
US5859014A (en) * 1995-06-09 1999-01-12 Syntex (U.S.A.) Inc. Pyrimidinedione, pyrimidinetrione, triazinedione and tetrahydroquinazolinedione derivatives as α1 -adrenergic receptor antagonists
WO2002083651A2 (en) * 2001-04-11 2002-10-24 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2006070292A2 (en) * 2004-10-12 2006-07-06 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2008145562A1 (en) * 2007-05-30 2008-12-04 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 February 1996 (1996-02-14), XP002560556, retrieved from STN Database accession no. 1996:94641 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 30 April 1994 (1994-04-30), XP002560557, retrieved from STN Database accession no. 1994:218388 *
G. T. CRISP ET AL.: "Palladium-catalyzed coupling of a propargylglycine derivative", TETRAHEDRON, vol. 48, no. 15, 1992, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM. NL, pages 3239 - 3250, XP002560558, ISSN: 0040-4020 *
H. MATSUHASHI ET AL.: "Synthesis of 5-substituted pyrimidine nucleosides through a palladium-catalyzed cross-coupling of alkylhalosilanes", HETEROCYCLES, vol. 42, no. 1, 1996, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM; NL, pages 375 - 384, ISSN: 0385-5414 *
N. G. KUNDU ET AL.: "Studies in uracil derivatives and analogs. 19. Synthesis of 5-(acylethynyl)uracils and their corresponding 2'-deoxyribonucleosides through palladium-catalyzed reactions", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY, vol. 21, 1993, Chemical Society, London; GB, pages 2657 - 2663, ISSN: 0300-922X *
S. J. HANNON ET AL.: "A new synthesis of N-blocked dihydrouracil and dihydroorotic acid derivatives using lithium tri-sec-butyl borohydride as reducing agent", TETRAHEDRON LETTERS, vol. 21, 1980, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM. NL, pages 1105 - 1108, XP002560559, ISSN: 0040-4039 *
See also references of EP2303848A2 *

Also Published As

Publication number Publication date
DE102008030091B4 (de) 2011-03-03
EP2303848A2 (de) 2011-04-06
US9181199B2 (en) 2015-11-10
US20110166096A1 (en) 2011-07-07
DE102008030091A1 (de) 2009-12-31
WO2009156182A2 (de) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2009156182A3 (de) Uracilderivate und deren verwendung
IL260158B (en) Pyrazine derivatives, preparations containing them and their uses
EP2153838A4 (de) Anti-norovirus-wirkstoff und zusammensetzung damit
IL199151A (en) Pyrimidine derivatives, their pharmaceutical preparations, their use in cancer treatment and their kits
AP2965A (en) Therapeutic compositions and the use thereof
IL204621A0 (en) Bicyclic - ?? - amino acid derivatives, compositions comprising the same and uses thereof
AP2490A (en) Therapeutic compositions and the use thereof
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
MX2009007254A (es) Composiciones de tableta en tableta.
IL211889A (en) Pyrazolo pyridine derivatives, preparations containing them and their use as nadph oxidase inhibitors
IL211892A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL201009A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
IL185484A0 (en) Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
IL206808A (en) Indolyl-pyridone history, their pharmaceutical preparations and their uses
IL211891B (en) Pyrazolo pyridine derivatives, preparations containing them and their uses
EP2262778B8 (de) 1-benzyl-3-hydroxymethylindazolderivate und ihre verwendung bei der behandlung von auf der expression von mcp-1, cx3cr1 und p40 basierten erkrankungen
EP2160152A4 (de) Kombinierter fibrinolytischer und antimikrobieller katheter und seine verwendungen
AU2008303948A8 (en) Use of the peptide Asn-Asp-Asp-Cys-Glu- Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu alone or in combination with the peptide Thr-Thr-Ser-Gln-Val- Arg-Pro-Arg as a therapeutic agent
BRPI0917728A2 (pt) composição, uso da composição, e, método de prevenção da formação de espuma em uma composição
IL204814A0 (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
PL2410047T3 (pl) Oksydoreduktaza i jej zastosowanie do redukcji sekodionu
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
IL208168A0 (en) Tetrahydroisoquinoline derivatives, compositions comprising the same and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09769031

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009769031

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13000900

Country of ref document: US